Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q2 2024 Results Conference Call August 1, 2024 8:30 AM ET Company Participants Meredith Kaya - SVP of IR & Strategic Finance Cedric Francois - Co-Founder & CEO Adam Townsend - COO Caroline Baumal - Chief Medical Officer Tim Sullivan - CFO Conference Call Participants Jonathan Miller - Evercore Anupam Rama - J.P. Morgan Yigal Nochomovitz - Citigroup Steven Seedhouse - Raymond James Colleen Kusy - Baird Phil Nadeau - TD Cowen Ivy Wang - Jefferies Eliana Merle - UBS ...

Apellis Pharmaceuticals, Inc. (APLS) incurred second-quarter 2024 loss of 28 cents per share (excluding loss on extinguishment of development liability), narrower than the Zacks Consensus Estimate of a loss of 33 cents. The company had incurred a loss of $1.02 per share in the year-ago quarter.Total revenues amounted to $199.7 million in the reported quarter, beating the Zacks Consensus Estimate of $189.5 million. In the year-ago quarter, the company had reported revenues of $95 million.The top line skyrock ...

Core Insights - Apellis Pharmaceuticals, Inc. reported a revenue of $199.69 million for the quarter ended June 2024, marking a significant increase of 110.3% year-over-year [1] - The earnings per share (EPS) was -$0.28, an improvement from -$1.02 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $189.47 million by 5.39%, while the EPS also surpassed the consensus estimate of -$0.33 by 15.15% [1] Revenue Breakdown - Product revenue, net was reported at $179.14 million, slightly below the nine-analyst average estimate of $182.18 million [3] - Licensing and other revenue reached $20.55 million, significantly higher than the average estimate of $7.63 million based on nine analysts [4] - Product revenue from EMPAVELI was $24.50 million, compared to the average estimate of $26.48 million from five analysts [5] - Product revenue from SYFOVRE was $154.60 million, which also fell short of the five-analyst average estimate of $157.98 million [6] Stock Performance - Over the past month, shares of Apellis Pharmaceuticals have returned +11.8%, outperforming the Zacks S&P 500 composite's +1.1% change [6] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [6]

Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $1.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15.15%. A quarter ago, it was expected that this company would post a loss of $0.54 per share when it actually produced a loss of $0.54, delivering no surprise.Over the last four quarters, the company has sur ...

Generated $199.7 million in 2Q 2024 revenues, including $179.1 million in U.S. net product sales $154.6 million for SYFOVRE® (pegcetacoplan injection) $24.5 million for EMPAVELI® (pegcetacoplan) Initiated a re-examination of the marketing authorization application of SYFOVRE with the European Medicines Agency (EMA); expect a final decision in 4Q 2024 Plan to report topline Phase 3 data with systemic pegcetacoplan in C3G / IC-MPGN in August 2024Cash and cash equivalents of $360.1 million as of June 30, 2024 ...

Generated $199.7 million in 2Q 2024 revenues, including $179.1 million in U.S. net product sales $154.6 million for SYFOVRE® (pegcetacoplan injection) $24.5 million for EMPAVELI® (pegcetacoplan) Initiated a re-examination of the marketing authorization application of SYFOVRE with the European Medicines Agency (EMA); expect a final decision in 4Q 2024 Plan to report topline Phase 3 data with systemic pegcetacoplan in C3G / IC-MPGN in August 2024Cash and cash equivalents of $360.1 million as of June 30, 2024 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-1537290 (State or other jur ...

The market expects Apellis Pharmaceuticals, Inc. (APLS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expecte ...

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Apellis Pharmaceuticals, Inc. related to misrepresentations regarding the clinical trials of SYFOVRE [1] Group 1: Legal Investigation - A federal securities lawsuit claims that Apellis insiders misrepresented the design of SYFOVRE's clinical trials, which was inadequate to identify retinal vasculitis incidents in patients [1] - The lawsuit indicates that the commercial adoption of SYFOVRE is subject to significant unknown risk factors due to these misrepresentations [1] - Consequently, statements made by the company regarding its business, operations, and prospects are deemed to lack a reasonable basis [1] Group 2: Shareholder Information - Shareholders who purchased Apellis stock prior to January 28, 2021 are encouraged to contact Kuehn Law for a free consultation regarding their rights [2] - Kuehn Law covers all case costs and does not charge its investor clients, emphasizing the importance of timely action for shareholders [2] Group 3: Importance of Participation - The involvement of shareholders is highlighted as crucial for maintaining the integrity and fairness of financial markets, reinforcing the idea that every investment and voice matters [3]

WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2024 financial results on Thursday, August 1, 2024, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the compa ...